Carisome^™ Posters, Papers, Abstracts and Presentations

Learn more about the promise of Carisome Technology from the data presented at recent meetings.

American Urological Association (AUA) 2011

Analysis of a Circulating Microvesicle-Based Assay in At-Risk Patients for the Detection of Prostate Cancer

American Academy of Cancer Research (AACR) 2011

Plasma-Derived Circulating Microvesicles Can Both Detect and Help Monitor Breast Cancer–Related Pathologies

Enriching for Rare Subpopulations of Circulating Microvesicles by the Depletion of Endothelial- and Leukocyte-Derived Microvesicles

Comparison of miR Expression Patterns in Plasma, Serum, and Cell Line Microvesicles

Subpopulations of Circulating Microvesicles Have Different MicroRNA Profiles

Detection of Lung Cancer From Plasma Using the Biosignature of Circulating Microvesicles

American Academy of Cancer Research (AACR) 2010

Plasma exosome-based biosignatures: A novel method for early diagnosis of colorectal cancer

Plasma exosomes are a robust biosignature for prostate cancer

Important differences between exosome biosignatures from prostate cancer patient plasma samples and prostate cancer cell lines

Identification and characterization of exosome subpopulations to provide the foundation for a novel exosome-based cancer diagnostic platform

American Society of Clinical Oncology (ASCO) 2010

A sensitive exosome-based biosignature for the diagnosis of prostate cancer

Circulating exosomes may provide an alternate platform to monitor disease progression compared to circulating tumor cells

Carisome^™ Microvesicle Technology

Caris Presents

Caris Life Sciences Molecular Oncology Services

Caris' scientific experts contribute to the advancement of science at various symposia and conferences worldwide.

“WE INTEND TO HELP RELIEVE THE SUFFERING OF AS MANY PEOPLE AS POSSIBLE”

David D. Halbert Chairman & CEO